Please login to the form below

Not currently logged in
Email:
Password:

Prexton

This page shows the latest Prexton news and features for those working in and with pharma, biotech and healthcare.

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

$1b purchase of  Prexton Therapeutics and phase 2 Parkinson’s disease therapy foliglurax.

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    For example, over the last five years, Lundbeck acquired Prexton Therapeutics, Agilent acquired Genohm and Boehringer Ingelheim acquired Amal Therapeutics, focused on cancer immunotherapy and therapeutic cancer vaccines.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....